Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334 (7 April), doi:10.1136/bmj.39174.288877.3B
Jane Smith, deputy editor
jsmith@bmj.com
| The first 150 words of the full text of this article appear below. |
Sexually transmitted infections are tricky: prevention is always going to be difficult, especially if it involves changing behaviour, but the case of human papillomavirus suggests that preventive methods can be controversial even when they don't demand behaviour changes. Rebecca Coombes explains why a new vaccine against human papillomavirus that is designed to prevent cervical cancer is causing controversy in the US (doi: 10.1136/bmj.39164.510127.AD). The vaccine is given to preteen girls and is expensive. Some think that a mandatory universal vaccination programme undermines parental responsibility and promotes underage sex; it doesn't help that the manufacturer has been heavily promoting the vaccine.
If preventing an infection isn't easy, the next best thing is to identify cases and treat them. Identification is difficult when an infection is initially asymptomatic, so when evidence from Sweden showed that screening could control transmission of chlamydial infection and reduce morbidity of the female reproductive tract several
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?